Treatment of mechanical valve thrombosis during pregnancy.
Pregnant patients with mechanical valves require anticoagulation. The risk of bleeding and embryopathy associated with oral anticoagulation must be weighed against the risk of valve thrombosis. In the presence of a mechanical valve thrombosis, an appropriate treatment modality must be selected, as it is critical for the health of mother and fetus. In this review, we present a pregnant patient with mechanical valve thrombosis (MVT) who underwent thrombolytic therapy, subsequent anticoagulation according to available guidelines, and delivered a healthy baby at full term.
Choi
Calvin
C
Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, Florida 32610-0277, USA.
Midwall
Scott
S
Chaille
Peter
P
Conti
C R
CR
D000328:Adult; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001803:Blood Transfusion; D002585:Cesarean Section; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005865:Gestational Age; D006350:Heart Valve Prosthesis / Q000009:adverse effects*; D006406:Hematoma / Q000139:chemically induced / Q000628:therapy; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D050498:Live Birth; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000175:diagnosis / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013923:Thromboembolism / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D014859:Warfarin; D006493:Heparin; D010959:Tissue Plasminogen Activator